Disclaimer

This presentation to be given on 3 April 2019 provides additional comment on the Interim Report of The a2 Milk Company Limited, a company incorporated in New Zealand (a2MC), and its subsidiaries, for the six months ended 31 December 2018 and the accompanying information released to the market on February 20, 2019. As such, it should be read in conjunction with the explanations and views in those documents. This presentation is provided for general information purposes only, and is not an offer to sell or a solicitation of an offer to buy securities. The information contained in this presentation is not intended to be relied upon as advice to investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Investors should assess their own individual financial circumstances and consider talking to a financial adviser or consultant before making any investment decision. We have not authorised anyone to provide you with any information other than that contained in this presentation or delivered by an officer of the Company.

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. You can identify these statements because they do not relate strictly to historical or current facts. Such statements may include words such as “anticipate,” “will,” “estimate,” “expect,” “look forward,” “strive,” “project,” “intend,” “should,” “plan,” “believe,” “hope,” “enable,” “potential,” and other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, product developments and launches, regulatory or competitive environments, outcome of litigation, and our intellectual property. These forward-looking statements may include, but are not limited to, statements regarding our competitive position, product development and commercialisation schedule, expectation of continued growth and the reasons for that growth, growth rates, strength, and current (2019) and future fiscal year outlook and projected results including projected revenue and expenses, net loss and gross margin. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements and to note they speak only as of the date of this presentation. We disclaim any intention or obligation to update or revise any financial or other projections or other forward-looking statements, whether because of new information, future events or otherwise.

All and any financial projections are based upon assumptions that are inherently uncertain and unpredictable. These assumptions and estimates may be incomplete or inaccurate or may not account sufficiently for unanticipated events and circumstances. For these reasons, actual results achieved during the periods covered will almost certainly vary from such projections, and such variations may be material and adverse. This information is presented as of the date of this presentation and is subject to change without notice.

All values are expressed in New Zealand dollars unless otherwise stated; and our financial statements are prepared in accordance with generally accepted accounting practice in New Zealand (NZ GAAP) and not U.S. general accepted accounting principles.

Also, this presentation includes certain financial measures that were not prepared in accordance with NZ GAAP. Reconciliations of those non-NZ GAAP financial measures to the most directly comparable NZ GAAP financial measures can be found in our annual report and half-yearly report. Any non-NZ GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by NZ GAAP, have no standardized meaning prescribed by NZ GAAP and may not be comparable to the calculation of similar measures of other companies.

All intellectual property, proprietary and other rights and interests in this presentation are owned by the Company.
The a2 Milk Company at a glance

- Single minded focus on providing high quality branded dairy nutritional products in targeted global markets

- We uniquely focus only on products based on the A2 beta casein protein type rather than conventional cows’ milk products containing both A1 and A2 protein types

- Our strong, modern brand is building momentum in the two largest consumer markets in the world

(all figures NZ$)

$613m
1H19 Revenue ↑ 41% YoY

20.9c
1H19 EPS¹

$10.5b
Market capitalisation²

¹ Basic earnings per share (EPS)
² Based on share price of NZ$14.30 at 29 March 2019 (quoted securities only)
Macro consumer trends support our momentum

- Growing consumer demand for health and wellness products
- Food safety, naturalness and provenance
- Growing middle class in Asia
What makes us so unique?

- Single-minded focus
- Unique, modern and premium brand
- Innovative and agile approach
- Focussed investment in brand, IP and growth
- Capital-smart approach
- Australia and New Zealand sourcing for Asia Pacific
Global strategic supply partnerships

We continue to be well supported by our key strategic supply partners

- Foundation infant nutrition partnership
- Exclusive supply rights for infant nutrition into ANZ & China
- 5 year minimum supply agreement signed July 2018
- Building capacity to support future growth:
  - Auckland canning facility
  - Pokeno facility

- Emerging markets & multi-products partnership
- Exclusive supply rights for infant formula and other products into new priority markets
- a2 Milk™ branded fresh milk launched in NZ (Aug-18)
- Building capacity to support future growth with the development of milk pools in Australia and New Zealand
The Company’s financial year ends 30 June; H1 refers to the first half period from 1 July to 31 December; H2 refers to the second half period from 1 January to 30 June. EBITDA is a non-GAAP measure and represents earnings before interest, tax, depreciation and amortisation, and is shown before non-recurring items.
Record first half results, step changing investment for the future

Record financial results in 1H19, continuing strong momentum

- Group revenue: $613.1 million\(^1\) +41.0%; EBITDA\(^2\): $218.4 million +52.7%
- Net profit after tax: $152.7 million +55.1%
- Strong balance sheet with closing cash balance: $287.9 million

Record market share positions underpin strong results in each region

- Infant formula consumption market share in China of 5.7\(^3\); China label revenue +82.6%, brand leadership in Australia at 35.7\(^4\)
- US sales growth +114.1\(^\%\) (USD) and over 10k store distribution
- Australian fresh milk value share 10.8\(^5\), revenue +11.7\(^\%\) (AUD)

Step changing investment for the long term health of our brand and core markets

- Accelerating strategic investment in consumer insights, brand and organisational capability
- Marketing spend +75\(^\%\) in first half (#1 priority China, #2 priority USA)
- Number of new senior and broader team hires, focusing on China, NPD and capacity for continued growth and resilience
- Building both depth and breadth of organisational capability and infrastructure

\(^1\) All figures quoted in New Zealand Dollars (NZ$) and all comparisons are with the six months ended 31 December 2017 (1H18), unless otherwise stated
\(^2\) Operating EBITDA is a non-GAAP measure and represents earnings before interest, tax, depreciation and amortisation
\(^3\) Kantar Infant Formula market tracking of China Tier 1 and Key A cities for 12 months ending 28 December 2018 by value
\(^4\) Aztec Australian Grocery and Pharmacy Scan 12 months ending 30 December 2018
\(^5\) Aztec Australian Grocery Weighted Scan 12 months ending 30 December 2018
Quarter 3 key regional update

China
• Pleasing progress for China label and English label (CBEC\(^1\)) infant formula sales
• Up-weighted 2H19 marketing program on track
• Continued strengthening of infant formula market share position
• Appointment of Li Xiao, CE Greater China, effective 29 April 2019

ANZ
• Continued strong infant formula and liquid milk sales with continuing growth in market share
• The business has not experienced any impact to infant formula sales from new e-commerce or CBEC regulations\(^2\) in China

USA
• Continuing positive momentum in sales velocities and distribution growth for liquid milk
• Recent portfolio extension to include premium and natural coffee creamers

\(^1\) Cross Border E-Commerce (CBEC)
\(^2\) CBEC policy framework as announced by Chinese Government on 30 November 2018
In the first half the Company has invested strongly in both internal and external capability to better understand our Chinese consumers, channel dynamics and ways of improving brand awareness.

Following a very strong first half performance, and encouraged by growing market share in China, the Company is now in a position to reinvest the benefits of scale into increased marketing activities in the second half. This is intended to drive brand awareness, predominantly in China, and the US. Increased brand and marketing investment is expected to continue into FY20.

The Company expects the Group revenue growth rate in the second half to continue broadly in line with the first half. The increased investment in brand building in 2H19 is expected to support revenue growth in FY20 and beyond.

Second half EBITDA margins will consequently be lower than first half, with full year FY19 EBITDA as a percentage of sales expected to be approximately 31-32%. This is due largely to:

- Marketing investment in 2H19 to approximately double 1H19
- Continued investment in building organisational capability; and
- A weaker Australian Dollar (vs New Zealand Dollar)

We do not anticipate any significant impact to gross margin % during FY19 as a result of recent increases in dairy pricing as reflected in Global Dairy Trade Indices. However, these increases are likely to have some impact in FY20.

\[1\] The Company’s forecast has been calculated using exchange rates as at 31 December 2018.
What is the a2 Milk® brand difference?

- The brand difference starts with specially selected cows
- The a2 Milk Company has significant years of knowledge and experience and takes great care in bringing our consumers the very best quality dairy nutritional products always free from the A1 protein
- A1 and A2 proteins digest differently - many people who have issues digesting conventional milk find they can enjoy a2 Milk®

Genetic mutation occurred in European herds and spread via migration and modern farming practices

Originally all cows produced milk containing only the A2 protein1

All conventional milk is a mix of A1 and A2 proteins1

a2MC milk naturally contains only the A2 protein and is free from A1 protein1

1 A1 and A2 protein refers to A1 and A2 beta casein protein types respectively
# 1H19 financial summary – step changing investment

<table>
<thead>
<tr>
<th>NZ$ million</th>
<th>1H19</th>
<th>1H18</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>613.1</td>
<td>434.7</td>
<td>+41%</td>
</tr>
<tr>
<td>Gross margin</td>
<td>340.6</td>
<td>216.5</td>
<td>+57%</td>
</tr>
<tr>
<td>Distribution</td>
<td>(14.8)</td>
<td>(13.0)</td>
<td>+14%</td>
</tr>
<tr>
<td>Marketing</td>
<td>(45.5)</td>
<td>(26.0)</td>
<td>+75%</td>
</tr>
<tr>
<td>Employee costs</td>
<td>(27.4)</td>
<td>(16.4)</td>
<td>+67%</td>
</tr>
<tr>
<td>Administration &amp; other</td>
<td>(34.5)</td>
<td>(18.0)</td>
<td>+91%</td>
</tr>
<tr>
<td>EBITDA</td>
<td>218.4</td>
<td>143.0</td>
<td>+53%</td>
</tr>
<tr>
<td>EBIT</td>
<td>217.4</td>
<td>141.9</td>
<td>+53%</td>
</tr>
<tr>
<td>NPAT</td>
<td>152.7</td>
<td>98.5</td>
<td>+55%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NZ$ million</th>
<th>Dec-18</th>
<th>Jun-18</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash on hand</td>
<td>287.9</td>
<td>340.5</td>
<td>-15%</td>
</tr>
<tr>
<td>Inventory</td>
<td>72.8</td>
<td>64.1</td>
<td>+13%</td>
</tr>
</tbody>
</table>

- Reflects continuing strong growth across key regions
- GM of 55.6% reflects benefits of scale and mix (higher proportion of infant formula sales), partially offset by currency movements (most notably a weaker AUD)
- Increased marketing investment primarily to support growth in China and the US
- Employee cost increases reflect capability build in core markets and corporate
- Reflects strategic investment in consumer insights and costs to support business expansion
- Cash on hand reflects strong NPAT contribution, offset by investment in Synlait
- Increase in infant formula inventories; includes $35.3m of goods in transit
1H19 cash position – strong balance sheet

**Group cash movement: 1H19**
(NZ$ million)

- **Cash on hand (Jun-18):** 340.5
- **Group NPAT:** +152.7
- **Working capital:** (47.3)
- **Investments in PPE & intangibles:** (2.4)
- **Investment in Synlait:** (162.3)
- **Depreciation, amortisation & other non-cash:** +6.9
- **FX and other:** +0.1
- **Cash on hand (Dec-18):** 287.9

- Working capital movement reflects timing of tax and supplier payments, impact of revenue phasing on debtors and increased infant formula inventory
- Increased investment in Synlait to 17.4% shareholding in August 2018
### Geographic and product segment performance

**Geographic segment revenue & EBITDA**

<table>
<thead>
<tr>
<th>NZ$ million</th>
<th>Australia &amp; New Zealand</th>
<th>China &amp; other Asia</th>
<th>UK &amp; USA</th>
<th>Corporate</th>
<th>Total Group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1H19</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>418.4</td>
<td>171.7</td>
<td>23.0</td>
<td>-</td>
<td>613.1</td>
</tr>
<tr>
<td>EBITDA¹</td>
<td>192.0</td>
<td>68.4</td>
<td>(14.6)</td>
<td>(27.4)</td>
<td>218.4</td>
</tr>
<tr>
<td>EBITDA %</td>
<td>45.9%</td>
<td>39.9%</td>
<td>NM</td>
<td>-</td>
<td>35.6%</td>
</tr>
</tbody>
</table>

| **1H18**    |                         |                    |          |           |             |
| Revenue     | 304.3                   | 114.4              | 16.0     | -         | 434.7       |
| EBITDA      | 116.4                   | 48.3               | (8.4)    | (13.3)    | 143.0       |
| EBITDA %    | 38.3%                   | 42.3%              | NM       | -         | 32.9%       |

| % Change    |                         |                    |          |           |             |
| Revenue     | 37.5%                   | 50.1%              | 43.1%    | -         | 41.0%       |
| EBITDA      | 64.9%                   | 41.6%              | NM       | 105.2%    | 52.7%       |

<table>
<thead>
<tr>
<th>Product segment revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid milk</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>83.4</td>
</tr>
<tr>
<td>69.4</td>
</tr>
<tr>
<td>20.2%</td>
</tr>
</tbody>
</table>

¹ EBITDA is a non-GAAP measure and represents earnings before interest, tax, depreciation and amortisation.
## Reconciliation of non-GAAP measures

<table>
<thead>
<tr>
<th>NZ$ million</th>
<th>1H19</th>
<th>1H18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia &amp; New Zealand segment EBITDA</td>
<td>192.0</td>
<td>116.4</td>
</tr>
<tr>
<td>China &amp; other Asia segment EBITDA</td>
<td>68.4</td>
<td>48.3</td>
</tr>
<tr>
<td>UK &amp; USA segment EBITDA¹</td>
<td>(14.6)</td>
<td>(8.4)</td>
</tr>
<tr>
<td>Corporate EBITDA</td>
<td>(27.4)</td>
<td>(13.4)</td>
</tr>
<tr>
<td><strong>EBITDA¹</strong></td>
<td>218.4</td>
<td>143.0</td>
</tr>
<tr>
<td>Depreciation/amortisation</td>
<td>(1.0)</td>
<td>(1.1)</td>
</tr>
<tr>
<td><strong>EBIT¹</strong></td>
<td>217.4</td>
<td>141.9</td>
</tr>
<tr>
<td>Net interest income</td>
<td>1.6</td>
<td>0.8</td>
</tr>
<tr>
<td>Income tax expense</td>
<td>(66.3)</td>
<td>(44.2)</td>
</tr>
<tr>
<td><strong>Net profit for the period</strong></td>
<td>152.7</td>
<td>98.5</td>
</tr>
</tbody>
</table>

¹EBITDA and EBIT are non-GAAP measures. However, the Company believes they assist in providing investors with a comprehensive understanding of the underlying performance of the business.
China regulatory environment

• The Chinese government issued a number of regulatory updates during the half with respect to e-commerce and CBEC across all products and services. A new e-commerce law (effective 1 Jan 2019) and CBEC policy framework (effective 31 March 2019) together confirmed:
  – A strengthening of compliance obligations for e-commerce operators (domestic and CBEC)
  – English label infant formula and milk powder products can continue to be sold via CBEC as imports for personal use
  – A continuation of preferential tax rates for imports via CBEC bonded warehouse zones
  – An increase to the number of approved CBEC bonded warehouse zones across China

• Synlait Milk facility registrations progressing:
  – Late December 2018, Synlait Milk obtained registration renewal of its Dunsandel plant with the GACC allowing Synlait to continue to export canned infant formula to China; Auckland plant has achieved GACC dairy registration and is progressing with the GACC infant nutrition process

---

1 Provided CBEC participants adhere to the responsibilities as outlined in the policy framework by 31 March 2019
2 General Administration of Customs of the People’s Republic of China